Better Therapeutics Management

Management criteria checks 0/4

Better Therapeutics' CEO is Frank Karbe, appointed in Jul 2022, has a tenure of 1.83 years. total yearly compensation is $1.44M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.85% of the company’s shares, worth $4.64K. The average tenure of the management team and the board of directors is 1.8 years and 2.6 years respectively.

Key information

Frank Karbe

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage	17.1%
CEO tenure	1.8yrs
CEO ownership	0.9%
Management average tenure	1.8yrs
Board average tenure	2.6yrs

Recent management updates

Recent updates

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Sep 22

Better Therapeutics GAAP EPS of -$0.42 in-line

Aug 11

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

May 12

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Nov 30

CEO Compensation Analysis

How has Frank Karbe's remuneration changed compared to Better Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$39m
Dec 31 2022	US$1m	US$246k	-US$40m

Compensation vs Market: Frank's total compensation ($USD1.44M) is above average for companies of similar size in the US market ($USD663.50K).

Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.

CEO

Frank Karbe (55 yo)

1.8yrs

Tenure

US$1,443,298

Compensation

Mr. Frank L. Karbe has been the Chief Executive Officer, President and Director at Better Therapeutics, Inc. since July 5, 2022 and serves its Interim Chief Financial Officer since November 2023. He served...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Perry	Co-Founder & Executive Chairman	2.6yrs	US$270.50k	35.58% $ 194.0k
Frank Karbe	CEO, Interim CFO	1.8yrs	US$1.44m	0.85% $ 4.6k
Mark Berman	Chief Medical Officer	2.6yrs	US$672.16k	0.59% $ 3.2k
Kristin Wynholds	Chief Product Officer	2.6yrs	US$617.48k	0.37% $ 2.0k
Andres Camacho	Senior VP of Technology & Head of Engineering	no data	no data	no data
Angela Willis	Senior Vice President of Market Access	less than a year	no data	no data
Jessica Meng	Chief Commercial Officer	less than a year	no data	no data
Leslie Miller	Controller	no data	no data	0.026% $ 143.5

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: BTTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Perry	Co-Founder & Executive Chairman	2.6yrs	US$270.50k	35.58% $ 194.0k
Frank Karbe	CEO, Interim CFO	1.8yrs	US$1.44m	0.85% $ 4.6k
Risa Lavizzo-Mourey	Independent Director	2.6yrs	US$60.50k	0.018% $ 100.0
Andrew Armanino	Independent Director	2.6yrs	US$65.50k	1.36% $ 7.4k
Richard Carmona	Independent Director	2.6yrs	US$159.56k	0.28% $ 1.5k
Geoffrey Parker	Independent Director	2.6yrs	US$66.00k	1.98% $ 10.8k
Elder Granger	Independent Director	2.5yrs	US$58.00k	0.066% $ 358.5

2.6yrs

Average Tenure

58yo

Average Age

Experienced Board: BTTX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Better Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

High number of new and inexperienced directors

Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

Head of Finance & Interim CFO recently bought US$97k worth of stock

Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board of Directors Starting July 5, 2022

Recent updates

Better Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price and Market Value of Listed Securities Requirements for Continued Listing on The Nasdaq Capital Market

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics Voluntarily Requests a Delisting of its Securities and Expects its Securities to Be Delisted in the Near Term

Better Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Better Therapeutics, Inc. announced that it has received $0.25 million in funding

Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone

Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Better Therapeutics Provides Non-Compliance Update

New major risk - Share price stability

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

Better Therapeutics, Inc. Announces CFO Changes, Effective November 27, 2023

New major risk - Financial position

Better Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Market cap size

Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Better Therapeutics, Inc. announced that it has received $2.115287 million in funding

Price target decreased by 20% to US$6.00

Better Therapeutics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Shareholder dilution

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. announced that it expects to receive $2.115287 million in funding

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Fda Authorization for Aspyrerx to Treat Adults with Type 2 Diabetes

Better Therapeutics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates increase by 33%, EPS downgraded

Better Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased by 34% to US$11.67

Better Therapeutics, Inc. Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

High number of new and inexperienced directors

Better Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Better Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial Officer

Better Therapeutics, Inc. Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 Diabetes

Better Therapeutics files for FDA approval of new type of digital therapy for diabetes

Head of Finance & Interim CFO recently bought US$97k worth of stock

Better Therapeutics GAAP EPS of -$0.42 in-line

Better Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Better Therapeutics, Inc. Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results

Better Therapeutics, Inc. Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001

Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board of Directors Starting July 5, 2022

Better Therapeutics: App-Based Therapeutics, Doesn't Look Novel

Better Therapeutics, Inc. to Report Q1, 2022 Results on May 13, 2022

High number of new and inexperienced directors

Independent Director recently bought US$86k worth of stock

Better Therapeutics, Inc. Announces Positive Primary Endpoint Data from the Pivotal Clinical Trial for the company's BT-001 Prescription Digital Therapeutic

Better Therapeutics, Inc. Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies

Better Therapeutics, Inc. Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

Better Therapeutics: Pioneering Prescription Digital Therapeutics Platform For Cardiometabolic Diseases

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age